Market research
MD1.F Medistim ASA
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 415M
- P/E ratio
- 27.02
- Analyst target
- Not available
- Dividend yield
- 35.%
- Beta
- 1.01
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- NO0010159684
- Market cap
- 415M
- P/E ratio
- 27.02
- Analyst target
- Not available
- Dividend yield
- 35.%
- Beta
- 1.01
About
About Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and ultrasound imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MD1.F discussion.
5 years, 5 months ago
Medistim ASA is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Medistim ASA's total revenue sank by 1.8% to $87M since the same quarter in the previous year.
Its net income has dropped by 12.4% to $14M since the same quarter in the previous year.
Finally, its free cash flow fell by 67.3% to $9M since the same quarter in the previous year.
Based on the above factors, Medistim ASA gets an overall score of 2/5.